Home > Insider Trading > Filing (0001209191-21-023819)

Filing Details

Accession Number:: 0001209191-21-023819
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-03-31 17:11:31
Reporting Period:: 2021-03-30

Accepted Time:: 2021-03-31 17:11:31
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1492426	Horizon Therapeutics Public Ltd Co	HZNP	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1820365	A. Daniel Camardo	C/O Horizon Therapeutics Plc Connaught House, 1St Fl, 1 Burlington Rd Dublin L2 4	Evp And President, U.s.	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Ordinary Shares	Disposition	2021-03-30	1,803	$83.58	43,997	No	4	S	Direct
Ordinary Shares	Disposition	2021-03-30	4,594	$84.97	39,403	No	4	S	Direct
Ordinary Shares	Disposition	2021-03-30	2,986	$85.88	36,417	No	4	S	Direct
Ordinary Shares	Disposition	2021-03-30	3,517	$86.87	32,900	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2021.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.23 to $84.095 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.53 to $85.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.55 to $86.545 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.60 to $87.33 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.